NASDAQ:COLL
Collegium Pharmaceutical Stock News
$37.51
+0 (+0%)
At Close: May 03, 2024
Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
04:01pm, Thursday, 21'st Oct 2021
STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, anno
6 High Earnings Yield Picks That You Shouldn't Miss Out On
10:05am, Tuesday, 28'th Sep 2021
Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
12:59pm, Monday, 20'th Sep 2021
COLL vs. ZTS: Which Stock Is the Better Value Option?
Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference
08:00am, Monday, 13'th Sep 2021
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2021 Results - Earnings Call Transcript
03:27pm, Saturday, 07'th Aug 2021
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2021 Results - Earnings Call Transcript
Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance
12:21pm, Friday, 06'th Aug 2021
Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36. The reported EPS of $1.79 was up from $0.23 a year ago and included a one-time non-cash a
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates
07:46pm, Thursday, 05'th Aug 2021
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stoc
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
04:47pm, Thursday, 29'th Jul 2021
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
04:01pm, Wednesday, 21'st Jul 2021
STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2
Collegium Pharmaceutical: Moving Closer To The Top
08:42am, Monday, 12'th Jul 2021
Collegium Pharmaceutical: Moving Closer To The Top
Collegium Announces Publication of Real-World Data in Journal of Pain Research
04:01pm, Wednesday, 16'th Jun 2021
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, tod
Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis
01:00pm, Wednesday, 02'nd Jun 2021
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
Collegium to Participate in Upcoming Investor Conference
04:05pm, Thursday, 20'th May 2021
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2021 Results - Earnings Call Transcript
01:58am, Sunday, 09'th May 2021
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2021 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates
07:32pm, Thursday, 06'th May 2021
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
